|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Division of Molecular and Cellular Pharmacology, Department of Pharmacology, Graduate School of Medicine, and 2The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan
Submitted 23 October 2007 ; accepted in final form 30 November 2007
Pharmacological treatment with various antiarrhythmic agents for the termination or prevention of atrial fibrillation (AF) is not yet satisfactory. This is in part because the drugs may not be sufficiently selective for the atrium, and they often cause ventricular arrhythmias. The ultrarapid-delayed rectifying potassium current (IKur) is found in the atrium but not in the ventricle, and it has been recognized as a potentially promising target for anti-AF drugs that would be without ventricular proarrhythmia. Several new agents that specifically block IKur have been developed. They block IKur in a voltage- and time-dependent manner. Here we use mathematical models of normal and electrically remodeled human atrial action potentials to examine the effects of the blockade kinetics of IKur on atrial action potential duration (APD). It was found that after AF remodeling, an IKur blocker with fast onset can effectively prolong APD at any stimulus frequency, whereas a blocker with slow onset prolongs APD in a frequency-dependent manner only when the recovery is slow. The results suggest that the voltage and time dependence of IKur blockade should be taken into account in the testing of anti-AF drugs. This modeling study suggests that a simple voltage-clamp protocol with a short pulse of
10 ms at 1 Hz may be useful to identify the effective anti-AF drugs among various IKur blockers.
ultrarapid-delayed rectifying potassium current; atrial action potential; computer simulation
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |